SEARCH

SEARCH BY CITATION

References

  • Airoldi, I., Di Carlo, E., Cocco, C., Taverniti, G., D’Antuono, T., Ognio, E., Watanabe, M., Ribatti, D., and Pistoia, V. (2007). Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc. Natl Acad. Sci. USA 104, 39964001.
  • Amersi, F.F., Terando, A.M., Goto, Y., Scolyer, R.A., Thompson, J.F., Tran, A.N., Faries, M.B., Morton, D.L., and Hoon, D.S. (2008). Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin. Cancer Res. 14, 638645.
  • Balentien, E., Mufson, B.E., Shattuck, R.L., Derynck, R., and Richmond, A. (1991). Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 6, 11151124.
  • Balkwill, F., Charles, K.A., and Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211217.
  • Balkwill, F., and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357, 539545.
  • Bar-Eli, M. (1999). Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67, 1218.
  • Bartolome, R.A., Ferreiro, S., Miquilena-Colina, M.E., et al. (2009). The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am. J. Pathol. 174, 602612.
  • Ben-Baruch, A. (2008). Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin. Exp. Metastasis 25, 345356.
  • Bennett, D.C., Cooper, P.J., and Hart, I.R. (1987). A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer 39, 414418.
  • Blum, D.L., Koyama, T., M’Koma, A.E., Iturregui, J.M., Martinez-Ferrer, M., Uwamariya, C., Smith Jr, J.A., Clark, P.E., and Bhowmick, N.A. (2008). Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin. Cancer Res. 14, 77907797.
  • Boldajipour, B., Mahabaleshwar, H., Kardash, E., Reichman-Fried, M., Blaser, H., Minina, S., Wilson, D., Xu, Q., and Raz, E. (2008). Control of chemokine-guided cell migration by ligand sequestration. Cell 132, 463473.
  • Bottazzi, B., Walter, S., Govoni, D., Colotta, F., and Mantovani, A. (1992). Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148, 12801285.
  • Brennecke, S., Deichmann, M., Naeher, H., and Kurzen, H. (2005). Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res. 15, 515522.
  • Brown, C.E., Vishwanath, R.P., Aguilar, B., Starr, R., Najbauer, J., Aboody, K.S., and Jensen, M.C. (2007). Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J. Immunol. 179, 33323341.
  • Cardones, A.R., Murakami, T., and Hwang, S.T. (2003). CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res. 63, 67516757.
  • Caunt, M., Hu, L., Tang, T., Brooks, P.C., Ibrahim, S., and Karpatkin, S. (2006). Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res. 66, 41254132.
  • Chen, G.S., Yu, H.S., Lan, C.C., Chow, K.C., Lin, T.Y., Kok, L.F., Lu, M.P., Liu, C.H., and Wu, M.T. (2006). CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br. J. Dermatol. 154, 910918.
  • Crawford, S., Belajic, D., Wei, J., et al. (2008). A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker. Mol. Cancer Ther. 7, 492499.
  • Croker, A.K., and Allan, A.L. (2008). Cancer stem cells: implications for the progression and treatment of metastatic disease. J. Cell Mol. Med. 12, 374390.
  • Devine, S.M., Flomenberg, N., Vesole, D.H., Liesveld, J., Weisdorf, D., Badel, K., Calandra, G., and DiPersio, J.F. (2004). Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J. Clin. Oncol. 22, 10951102.
  • Dhawan, P., and Richmond, A. (2002). Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72, 918.
  • Dhawan, P., Su, Y., Thu, Y.M., Yu, Y., Baugher, P., Ellis, D.L., Sobolik-Delmaire, T., Kelley, M., Cheung, T.C., Ware, C.F., and Richmond, A. (2008). The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J. Biol. Chem. 283, 1539915408.
  • Fierro, F.A., Brenner, S., Oelschlaegel, U., Jacobi, A., Knoth, H., Ehninger, G., Illmer, T., and Bornhauser, M. (2008). Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia. Leukemia 23, 393396.
  • Forster, R., Ohl, L., and Henning, G. (2001). Lessons learned from lymphocytes: CC chemokine receptor-7 involved in lymphogenic metastasis of melanoma. J. Natl. Cancer Inst. 93, 15881589.
  • Fruehauf, S., Seeger, T., Maier, P., et al. (2006). The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp. Hematol. 34, 10521059.
  • Fushimi, T., O’Connor, T.P., and Crystal, R.G. (2006). Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res. 66, 35133522.
  • Gallagher, P.G., Bao, Y., Prorock, A., Zigrino, P., Nischt, R., Politi, V., Mauch, C., Dragulev, B., and Fox, J.W. (2005). Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res. 65, 41344146.
  • Gazzaniga, S., Bravo, A.I., Guglielmotti, A., Van Rooijen, N., Maschi, F., Vecchi, A., Mantovani, A., Mordoh, J., and Wainstok, R. (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol. 127, 20312041.
  • Gebhardt, C., Averbeck, M., Viertel, A., Kauer, F., Saalbach, A., Anderegg, U., and Simon, J.C. (2007). Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp. Dermatol. 16, 636643.
  • Ghosh, S., Spagnoli, G.C., Martin, I., Ploegert, S., Demougin, P., Heberer, M., and Reschner, A. (2005). Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J. Cell. Physiol. 204, 522531.
  • Gonsiorek, W., Fan, X., Hesk, D., et al. (2007). Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J. Pharmacol. Exp. Ther. 322, 477485.
  • Gordon, M.A., Gil, J., Lu, B., et al. (2006). Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7, 6788.
  • Graves, D.T., Barnhill, R., Galanopoulos, T., and Antoniades, H.N. (1992). Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am. J. Pathol. 140, 914.
  • Guleng, B., Tateishi, K., Ohta, M., et al. (2005). Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res. 65, 58645871.
  • Hagemann, T., Lawrence, T., McNeish, I., Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C., and Balkwill, F.R. (2008). “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205, 12611268.
  • Haghnegahdar, H., Du, J., Wang, D., Strieter, R.M., Burdick, M.D., Nanney, L.B., Cardwell, N., Luan, J., Shattuck-Brandt, R., and Richmond, A. (2000). The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J. Leukoc. Biol. 67, 5362.
  • Hahn, M.A., Hahn, T., Lee, D.H., Esworthy, R.S., Kim, B.W., Riggs, A.D., Chu, F.F., and Pfeifer, G.P. (2008). Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 68, 1028010289.
  • Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B.L., Federman, S., Miller III, J.R., Allen, R.E., Singer, M.I., et al. (2005). The gene expression signatures of melanoma progression. Proc. Natl Acad. Sci. USA 102, 60926097.
  • Holm, N.T., Abreo, F., Johnson, L.W., Li, B.D., and Chu, Q.D. (2009). Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res. Treat 113, 293299.
  • Holm, N.T., Byrnes, K., Li, B.D., Turnage, R.H., Abreo, F., Mathis, J.M., and Chu, Q.D. (2007). Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J. Surg. Res. 141, 5359.
  • Horton, L.W., Yu, Y., Zaja-Milatovic, S., Strieter, R.M., and Richmond, A. (2007). Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res. 67, 97919799.
  • Hu, K., Xiong, J., Ji, K., Sun, H., Wang, J., and Liu, H. (2007). Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominant [correction of dominanted] cytokines and inhibits melanoma metastasis. Immunol. Lett. 113, 1928.
  • Kakinuma, T., and Hwang, S.T. (2006). Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc Biol. 79, 639651.
  • Kawada, K., Sonoshita, M., Sakashita, H., Takabayashi, A., Yamaoka, Y., Manabe, T., Inaba, K., Minato, N., Oshima, M., and Taketo, M.M. (2004). Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 64, 40104017.
  • Keeley, E.C., Mehrad, B., and Strieter, R.M. (2008). Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 28, 19281936.
  • Kim, J., Mori, T., Chen, S.L., Amersi, F.F., Martinez, S.R., Kuo, C., Turner, R.R., Ye, X., Bilchik, A.J., Morton, D.L., and Hoon, D.S. (2006). Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann. Surg. 244, 113120.
  • Kim, S.Y., Lee, C.H., Midura, B.V., et al. (2008). Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis 25, 201211.
  • Koga, M., Kai, H., Egami, K., et al. (2008). Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem. Biophys. Res. Commun. 365, 279284.
  • Kucia, M., Reca, R., Miekus, K., Wanzeck, J., Wojakowski, W., Janowska-Wieczorek, A., Ratajczak, J., and Ratajczak, M.Z. (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879894.
  • Lee, C.H., Kakinuma, T., Wang, J., Zhang, H., Palmer, D.C., Restifo, N.P., and Hwang, S.T. (2006). Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol .Cancer Ther. 5, 25922599.
  • Lentsch, A.B. (2002). The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? FASEB J. 16, 10931095.
  • Lesinski, G.B., Badgwell, B., Zimmerer, J., Crespin, T., Hu, Y., Abood, G., and Carson III, W.E. (2004). IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J. Immunol. 172, 73687376.
  • Li, H., Alizadeh, H., and Niederkorn, J.Y. (2008). Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Invest. Ophthalmol. Vis. Sci. 49, 636643.
  • Liang, Z., Brooks, J., Willard, M., Liang, K., Yoon, Y., Kang, S., and Shim, H. (2007). CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem. Biophys. Res. Commun. 359, 716722.
  • Lu, X.L., Jiang, X.B., Liu, R.E., and Zhang, S.M. (2008). The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 26, 53525357.
  • Luan, J., Shattuck-Brandt, R., Haghnegahdar, H., Owen, J.D., Strieter, R., Burdick, M., Nirodi, C., Beauchamp, D., Johnson, K.N., and Richmond, A. (1997). Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J. Leukoc. Biol. 62, 588597.
  • Luca, M., Huang, S., Gershenwald, J.E., Singh, R.K., Reich, R., and Bar-Eli, M. (1997). Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151, 11051113.
  • Lurje, G., Zhang, W., Schultheis, A.M., Yang, D., Groshen, S., Hendifar, A.E., Husain, H., Gordon, M.A., Nagashima, F., Chang, H.M., and Lenz, H.J. (2008). Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann. Oncol. 19, 17341741.
  • Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe’er, J., Trent, J.M., Meltzer, P.S., and Hendrix, M.J. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739752.
  • Mantovani, A. (2009). Cancer: inflaming metastasis. Nature 457, 3637.
  • Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. Nature 454, 436444.
  • Marchesi, F., Piemonti, L., Fedele, G., et al. (2008). The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 68, 90609069.
  • Mehrad, B., Keane, M.P., and Strieter, R.M. (2007). Chemokines as mediators of angiogenesis. Thromb. Haemost. 97, 755762.
  • Meijer, J., Ogink, J., and Roos, E. (2008). Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br. J. Cancer 99, 14931501.
  • Melnikova, V.O., and Bar-Eli, M. (2006). Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 19, 395405.
  • Miao, Z., Luker, K.E., Summers, B.C., et al. (2007). CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl Acad. Sci. USA 104, 1573515740.
  • Monteagudo, C., Martin, J.M., Jorda, E., and Llombart-Bosch, A. (2007). CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J. Clin. Pathol. 60, 596599.
  • Mourad-Zeidan, A.A., Melnikova, V.O., Wang, H., Raz, A., and Bar-Eli, M. (2008). Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am. J. Pathol. 173, 18391852.
  • Mrowietz, U., Schwenk, U., Maune, S., Bartels, J., Kupper, M., Fichtner, I., Schroder, J.M., and Schadendorf, D. (1999). The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br. J. Cancer 79, 10251031.
  • Mullins, I.M., Slingluff, C.L., Lee, J.K., Garbee, C.F., Shu, J., Anderson, S.G., Mayer, M.E., Knaus, W.A., and Mullins, D.W. (2004). CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 64, 76977701.
  • Murakami, T., Cardones, A.R., and Hwang, S.T. (2004). Chemokine receptors and melanoma metastasis. J. Dermatol. Sci. 36, 7178.
  • Murakami, T., Maki, W., Cardones, A.R., Fang, H., Tun Kyi, A., Nestle, F.O., and Hwang, S.T. (2002). Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 62, 73287334.
  • Navarini-Meury, A.A., and Conrad, C. (2008). Melanoma and innate immunity – active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin. Cancer Biol. doi: DOI: 10.1016/jsemcancer.2008.10.012.
  • Norgauer, J., Metzner, B., and Schraufstatter, I. (1996). Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J. Immunol. 156, 11321137.
  • Okada, Y., Okada, N., Mizuguchi, H., Takahashi, K., Hayakawa, T., Mayumi, T., and Mizuno, N. (2004). Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim. Biophys. Acta. 1670, 172180.
  • Ottaiano, A., Franco, R., Aiello Talamanca, A., et al. (2006). Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res. 12, 27952803.
  • Otto, K., Starz, H., Becker, J.C., and Schrama, D. (2007). Overexpression of matrix metalloproteinases, chemokines, and chemokine receptors relevant for metastasis in experimental models not an indication of lymph node metastases in human melanoma. Arch. Dermatol. 143, 947948.
  • Owen, J.D., Strieter, R., Burdick, M., Haghnegahdar, H., Nanney, L., Shattuck-Brandt, R., and Richmond, A. (1997). Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int. J. Cancer 73, 94103.
  • Palmer, K., Hitt, M., Emtage, P.C., Gyorffy, S., and Gauldie, J. (2001). Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 8, 282290.
  • Payne, A.S., and Cornelius, L.A. (2002). The role of chemokines in melanoma tumor growth and metastasis. J. Invest. Dermatol. 118, 915922.
  • Peng, H.H., Liang, S., Henderson, A.J., and Dong, C. (2007). Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp. Cell Res. 313, 551559.
  • Petit, I., Jin, D., and Rafii, S. (2007). The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 28, 299307.
  • Raman, D., Baugher, P.J., Thu, Y.M., and Richmond, A. (2007). Role of chemokines in tumor growth. Cancer Lett. 256, 137165.
  • Ramjeesingh, R., Leung, R., and Siu, C.H. (2003). Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J. 17, 12921294.
  • Ren, T., Chen, Q., Tian, Z., and Wei, H. (2007). Down-regulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice. Biochem. Biophys. Res. Commun. 364, 978984.
  • Richmond, A. (2002). NF-kappa B, chemokine gene transcription and tumour growth. Nat. Rev. Immunol. 2, 664674.
  • Richmond, A. (2008). CCR9 homes metastatic melanoma cells to the small bowel. Clin. Cancer Res. 14, 621623.
  • Salcedo, R., and Oppenheim, J.J. (2003). Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10, 359370.
  • Scala, S., Ierano, C., Ottaiano, A., et al. (2007). CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol. Immunother. 56, 15891595.
  • Schadendorf, D., Moller, A., Algermissen, B., Worm, M., Sticherling, M., and Czarnetzki, B.M. (1993). IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151, 26672675.
  • Schutyser, E., Su, Y., Yu, Y., Gouwy, M., Zaja-Milatovic, S., Van Damme, J., and Richmond, A. (2007). Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur. Cytokine Netw. 18, 5970.
  • Seidl, H., Richtig, E., Tilz, H., Stefan, M., Schmidbauer, U., Asslaber, M., Zatloukal, K., Herlyn, M., and Schaider, H. (2007). Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum. Pathol. 38, 768780.
  • Shen, H., Schuster, R., Stringer, K.F., Waltz, S.E., and Lentsch, A.B. (2006). The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J. 20, 5964.
  • Shields, J.D., Emmett, M.S., Dunn, D.B., Joory, K.D., Sage, L.M., Rigby, H., Mortimer, P.S., Orlando, A., Levick, J.R., and Bates, D.O. (2007). Chemokine-mediated migration of melanoma cells towards lymphatics–a mechanism contributing to metastasis. Oncogene 26, 29973005.
  • Shiozawa, Y., Havens, A.M., Pienta, K.J., and Taichman, R.S. (2008). The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22, 941950.
  • Simonetti, O., Goteri, G., Lucarini, G., Filosa, A., Pieramici, T., Rubini, C., Biagini, G., and Offidani, A. (2006). Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur. J. Cancer 42, 11811187.
  • Singh, S., Varney, M., and Singh, R.K. (2009). Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69, 411415.
  • Stathopoulos, G.T., Psallidas, I., Moustaki, A., et al. (2008). A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J. Natl. Cancer Inst. 100, 14641476.
  • Stephan, C., Schnorr, D., Loening, S.A., and Jung, K. (2005). Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur. Urol. 48, 386399. Eur. Urol. 48, 1059–1060; author reply 1060–1051.
  • Struyf, S., Burdick, M.D., Peeters, E., Van den Broeck, K., Dillen, C., Proost, P., Van Damme, J., and Strieter, R.M. (2007). Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 67, 59405948.
  • Takenaga, M., Tamamura, H., Hiramatsu, K., Nakamura, N., Yamaguchi, Y., Kitagawa, A., Kawai, S., Nakashima, H., Fujii, N., and Igarashi, R. (2004). A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem. Biophys. Res. Commun. 320, 226232.
  • Takeuchi, H., Fujimoto, A., Tanaka, M., Yamano, T., Hsueh, E., and Hoon, D.S. (2004). CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin. Cancer Res. 10, 23512358.
  • Takeuchi, H., Kitago, M., and Hoon, D.S. (2007). Effects of chemokines on tumor metastasis. Cancer Treat. Res. 135, 177184.
  • Taxman, D.J., MacKeigan, J.P., Clements, C., Bergstralh, D.T., and Ting, J.P. (2003). Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Cancer Res. 63, 50955104.
  • Thanarajasingam, U., Sanz, L., Diaz, R., Qiao, J., Sanchez-Perez, L., Kottke, T., Thompson, J., Chester, J., and Vile, R.G. (2007). Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res. 67, 300308.
  • Thelen, M., and Stein, J.V. (2008). How chemokines invite leukocytes to dance. Nat. Immunol. 9, 953959.
  • Tsuzuki, H., Takahashi, N., Kojima, A., Narita, N., Sunaga, H., Takabayashi, T., and Fujieda, S. (2006). Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris. Nasus. Larynx 33, 3742.
  • Ugurel, S., Rappl, G., Tilgen, W., and Reinhold, U. (2001). Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19, 577583.
  • Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Brocker, E.B., Houben, R., Zapatka, M., Fink, W., Kaufman, H.L., and Becker, J.C. (2008). Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol. Immunother. 57, 685691.
  • Van Deventer, H.W., O’Connor Jr, W., Brickey, W.J., Aris, R.M., Ting, J.P., and Serody, J.S. (2005). C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res. 65, 33743379.
  • Varney, M.L., Johansson, S.L., and Singh, R.K. (2006). Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125, 209216.
  • Varney, M.L., Li, A., Dave, B.J., Bucana, C.D., Johansson, S.L., and Singh, R.K. (2003). Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin. Exp. Metastasis 20, 723731.
  • Wang, B., Hendricks, D.T., Wamunyokoli, F., and Parker, M.I. (2006). A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 66, 30713077.
  • Wang, J., Shiozawa, Y., Wang, Y., Jung, Y., Pienta, K.J., Mehra, R., Loberg, R., and Taichman, R.S. (2008). The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 283, 42834294.
  • Wang, J.M., Taraboletti, G., Matsushima, K., Van Damme, J., and Mantovani, A. (1990). Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem. Biophys. Res. Commun. 169, 165170.
  • Wells, T.N., Power, C.A., Shaw, J.P., and Proudfoot, A.E. (2006). Chemokine blockers–therapeutics in the making? Trends Pharmacol. Sci. 27, 4147.
  • Wetzel, K., Struyf, S., Van Damme, J., Kayser, T., Vecchi, A., Sozzani, S., Rommelaere, J., Cornelis, J.J., and Dinsart, C. (2007). MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int. J. Cancer 120, 13641371.
  • Wiley, H.E., Gonzalez, E.B., Maki, W., Wu, M.T., and Hwang, S.T. (2001). Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93, 16381643.
  • Wilson, C., Wilson, T., Johnston, P.G., Longley, D.B., and Waugh, D.J. (2008). Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol. Cancer Ther. 7, 26492661.
  • Yamano, T., Kaneda, Y., Huang, S., Hiramatsu, S.H., and Hoon, D.S. (2006). Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol. Ther. 13, 194202.
  • Yang, J., Amiri, K.I., Burke, J.R., Schmid, J.A., and Richmond, A. (2006). BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin. Cancer Res. 12, 950960.
  • Yang, J., Luan, J., Yu, Y., Li, C., DePinho, R.A., Chin, L., and Richmond, A. (2001). Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame. Cancer Res. 61, 81508157.
  • Yang, J., Pan, W.H., Clawson, G.A., and Richmond, A. (2007). Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res. 67, 31273134.
  • Yang, J., and Richmond, A. (2001). Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res. 61, 49014909.
  • Yang, J., and Richmond, A. (2004). The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9, 846855.
  • Zagzag, D., Lukyanov, Y., Lan, L., Ali, M.A., Esencay, M., Mendez, O., Yee, H., Voura, E.B., and Newcomb, E.W. (2006). Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab. Invest. 86, 12211232.
  • Zhang, T., Somasundaram, R., Berencsi, K., Caputo, L., Gimotty, P., Rani, P., Guerry, D., Swoboda, R., and Herlyn, D. (2006a). Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur. J. Immunol 36, 457467.
  • Zhang, T., Somasundaram, R., Berencsi, K., et al. (2005). CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J. Immunol. 174, 58565863.
  • Zhang, T., Somasundaram, R., Berking, C., et al. (2006b). Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells. Cancer Biol. Ther. 5, 13041312.
  • Zigler, M., Villares, G.J., Lev, D.C., Melnikova, V.O., and Bar-Eli, M. (2008). Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am. J. Clin. Dermatol. 9, 307311.
  • Zlotnik, A., Yoshie, O., and Nomiyama, H. (2006). The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 7, 243.